曲妥珠单抗和拉帕替尼对人表皮生长因子受体 2 阳性乳腺癌治疗的影响。

Effects of trastuzumab and lapatinib on HER2 positive breast cancer treatment.

机构信息

Department of Clinnical Pharmacy, Tonglu First People's Hospital, Zhejiang, Tonglu, Hangzhou, Zhejiang, China, e-mail:

Department of Orthopedics, Tonglu First People's Hospital, Tonglu, Hangzhou, Zhejiang, China.

出版信息

J Biol Regul Homeost Agents. 2019;33(2):551-555.

Abstract

This study aimed to evaluate the clinical efficacy of trastuzumab combined with lapatinib in the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer. One hundred and fifty-four patients with breast cancer were randomly divided into a trastuzumab group (group A, 52 cases), a lapatinib group (group B, 48 cases) and a combination group (group C, 54 cases).

摘要

本研究旨在评估曲妥珠单抗联合拉帕替尼治疗人表皮生长因子受体 2（HER2）阳性乳腺癌的临床疗效。将 154 例乳腺癌患者随机分为曲妥珠单抗组（A 组，52 例）、拉帕替尼组（B 组，48 例）和联合组（C 组，54 例）。